- Home
- Publications
- Publication Search
- Publication Details
Title
The expanding role for small molecules in immuno-oncology
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 21, Issue 11, Pages 821-840
Publisher
Springer Science and Business Media LLC
Online
2022-08-19
DOI
10.1038/s41573-022-00538-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
- (2022) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- LAG3 pushes immuno-oncology’s leading edge
- (2022) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hallmarks of Cancer: New Dimensions
- (2022) Douglas Hanahan Cancer Discovery
- Ablation of Cbl-b and c-Cbl in dendritic cells causes spontaneous liver cirrhosis via altering multiple properties of CD103+ cDC1s
- (2022) Fei Xu et al. Cell Death Discovery
- ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680 + chemotherapy + zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC).
- (2021) Gulam Abbas Manji et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
- (2021) Dan You et al. Journal for ImmunoTherapy of Cancer
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Potent Reverse Indazole Inhibitors for HPK1
- (2021) Elsie C. Yu et al. ACS Medicinal Chemistry Letters
- Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1
- (2021) Andrew P. Degnan et al. ACS Medicinal Chemistry Letters
- Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
- (2021) Jang-June Park et al. Nature Communications
- DGKA Mediates Resistance to PD-1 Blockade
- (2021) Lingyi Fu et al. Cancer Immunology Research
- Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program
- (2021) Javier Arranz-Nicolás et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020)
- (2021) Ian D Linney et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
- (2021) David M. Briere et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds
- (2021) Brandon A. Vara et al. ACS Medicinal Chemistry Letters
- TREX1 as a Novel Immunotherapeutic Target
- (2021) Wayne O. Hemphill et al. Frontiers in Immunology
- Uncovering the Invisible: Mono-ADP-ribosylation Moved into the Spotlight
- (2021) Ann-Katrin Hopp et al. Cells
- MO10-6 Phase 1 study of retifanlimab (anti-PD-1) and INCB001158 (arginase inhibitor), alone or in combination, in solid tumors
- (2021) Takafumi Koyama et al. ANNALS OF ONCOLOGY
- 1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)
- (2021) H. Gelderblom et al. ANNALS OF ONCOLOGY
- ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- (2021) Sumit Kumar Subudhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Vimseltinib: A precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages
- (2021) Bryan D Smith et al. MOLECULAR CANCER THERAPEUTICS
- Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
- (2021) Ravi B. Patel et al. Science Translational Medicine
- Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology
- (2021) Min Lu et al. ACS Medicinal Chemistry Letters
- p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition
- (2021) Daniel Baumann et al. Journal for ImmunoTherapy of Cancer
- STING Agonists as Cancer Therapeutics
- (2021) Afsaneh Amouzegar et al. Cancers
- PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
- (2021) Pottayil G. Sasikumar et al. Communications Biology
- 393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers
- (2021) Samuel Klempner et al. Journal for ImmunoTherapy of Cancer
- Clinical significance of chemokine receptor antagonists
- (2020) Miao Miao et al. Expert Opinion on Drug Metabolism & Toxicology
- Allosteric inhibition of SHP2 stimulates anti-tumor immunity by transforming the immunosuppressive environment
- (2020) Elsa Quintana et al. CANCER RESEARCH
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
- (2020) Daniel Baumann et al. Nature Communications
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
- (2020) Lorenzo Galluzzi et al. Journal for ImmunoTherapy of Cancer
- Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
- (2020) Chunyong Ding et al. Acta Pharmaceutica Sinica B
- Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
- (2020) Min-Hee Oh et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of AB680: A Potent and Selective Inhibitor of CD73
- (2020) Kenneth V. Lawson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
- (2020) Jackie E. Bader et al. MOLECULAR CELL
- TGFβ biology in cancer progression and immunotherapy
- (2020) Rik Derynck et al. Nature Reviews Clinical Oncology
- The adenosine pathway in immuno-oncology
- (2020) Bertrand Allard et al. Nature Reviews Clinical Oncology
- 598TiP A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours
- (2020) J.J. Luke et al. ANNALS OF ONCOLOGY
- Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches
- (2020) Elizabeth A. Thompson et al. Annual Review of Medicine
- Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies
- (2020) Jingwen Si et al. CANCER CELL
- IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
- (2020) Ahmed Sadik et al. CELL
- Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling
- (2020) Huai-Xiang Hao et al. CLINICAL CANCER RESEARCH
- A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model
- (2020) D. Ciccone et al. EUROPEAN JOURNAL OF CANCER
- Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production
- (2020) Xiaohui Du et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
- (2020) Matthew J. LaMarche et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
- (2020) Reinhard Dummer et al. NATURE MEDICINE
- Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors
- (2020) Aung Naing et al. Journal for ImmunoTherapy of Cancer
- Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
- (2020) Leila Motedayen Aval et al. Journal of Clinical Medicine
- Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
- (2020) Aaron Balog et al. MOLECULAR CANCER THERAPEUTICS
- The glutaminase inhibitor CB-839 (Telaglenastat) enhances the anti-melanoma activity of T cell mediated immunotherapies.
- (2020) Sruthy Varghese et al. MOLECULAR CANCER THERAPEUTICS
- KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
- (2020) Pier Francesco Ferrucci et al. Journal for ImmunoTherapy of Cancer
- Human and mouse PD-L1: similar molecular structure, but different druggability profiles
- (2020) Katarzyna Magiera-Mularz et al. iScience
- Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
- (2019) Christine Ménétrier-Caux et al. Journal for ImmunoTherapy of Cancer
- Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity
- (2019) Juan J. Miret et al. Journal for ImmunoTherapy of Cancer
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Target Exposure and Pharmacodynamics Study of the Indoleamine 2,3-Dioxygenase-1 (IDO-1) Inhibitor Epacadostat in the CT26 Mouse Tumor Model
- (2019) Lauranne Poncelet et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
- (2019) Wenjun Ouyang et al. IMMUNITY
- STING pathway agonism as a cancer therapeutic
- (2019) Blake A. Flood et al. IMMUNOLOGICAL REVIEWS
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- DNA sensing by the cGAS–STING pathway in health and disease
- (2019) Mona Motwani et al. NATURE REVIEWS GENETICS
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation
- (2019) Daniela Pende et al. Frontiers in Immunology
- TAM receptors attenuate murine NK‐cell responses via E3 ubiquitin ligase Cbl‐b
- (2019) Leilani M. Chirino et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
- (2019) Arsen Osipov et al. Journal for ImmunoTherapy of Cancer
- 440OPhase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours
- (2019) A Naing et al. ANNALS OF ONCOLOGY
- 1209PExcellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1
- (2019) V Radhakrishnan et al. ANNALS OF ONCOLOGY
- Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
- (2019) Antoni Ribas et al. CLINICAL CANCER RESEARCH
- Structure activity relationship studies on Amb639752: toward the identification of a common pharmacophoric structure for DGKα inhibitors
- (2019) Suresh Velnati et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors—A STING in the Tale of ENPP1
- (2019) Kenneth I. Onyedibe et al. MOLECULES
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Monalizumab: inhibiting the novel immune checkpoint NKG2A
- (2019) Thorbald van Hall et al. Journal for ImmunoTherapy of Cancer
- The therapeutic potential of targeting tryptophan catabolism in cancer
- (2019) Christiane A. Opitz et al. BRITISH JOURNAL OF CANCER
- Adenosine Metabolism: Emerging Concepts for Cancer Therapy
- (2019) Detlev Boison et al. CANCER CELL
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019
- (2019) Claus Garbe et al. EUROPEAN JOURNAL OF CANCER
- Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals
- (2018) Javier Arranz-Nicolás et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Research of novel anticancer agents targeting arginase inhibition
- (2018) Thanh-Nhat Pham et al. DRUG DISCOVERY TODAY
- BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
- (2018) Jan Dörrie et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cytokines in the Treatment of Cancer
- (2018) Kevin C. Conlon et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
- (2018) Alexander J. Muller et al. Seminars in Immunopathology
- Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers
- (2018) Lisa Seitz et al. INVESTIGATIONAL NEW DRUGS
- Recent clinical trends in Toll-like receptor targeting therapeutics
- (2018) Muhammad Ayaz Anwar et al. MEDICINAL RESEARCH REVIEWS
- Design of amidobenzimidazole STING receptor agonists with systemic activity
- (2018) Joshi M. Ramanjulu et al. NATURE
- Phosphatases start shedding their stigma of undruggability
- (2018) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function
- (2018) Sairy Hernandez et al. Cell Reports
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy
- (2018) Melody Smith et al. OncoImmunology
- Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death
- (2017) Bridget Larkin et al. JOURNAL OF IMMUNOLOGY
- Tumor-related interleukins: old validated targets for new anti-cancer drug development
- (2017) Sarra Setrerrahmane et al. Molecular Cancer
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
- (2017) Marta Łuksza et al. NATURE
- Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
- (2017) Sathana Dushyanthen et al. Nature Communications
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
- (2017) Susanne M. Steggerda et al. Journal for ImmunoTherapy of Cancer
- Abstract LB-085: RG70099: A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment
- (2016) Gabor Gyulveszi et al. CANCER RESEARCH
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- A novel diacylglycerol kinase α-selective inhibitor, CU-3, induces cancer cell apoptosis and enhances immune response
- (2016) Ke Liu et al. JOURNAL OF LIPID RESEARCH
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- Inhibition of CBLB protects from lethal Candida albicans sepsis
- (2016) Gerald Wirnsberger et al. NATURE MEDICINE
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Redundant and specialized roles for diacylglycerol kinases and in the control of T cell functions
- (2015) I. Merida et al. Science Signaling
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template
- (2015) Blythe D. Sather et al. Science Translational Medicine
- Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
- (2015) Miguel F. Sanmamed et al. SEMINARS IN ONCOLOGY
- Redundant and specialized roles for diacylglycerol kinases and in the control of T cell functions
- (2015) I. Merida et al. Science Signaling
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
- (2014) E. K. Moon et al. CLINICAL CANCER RESEARCH
- The Roles of Diacylglycerol Kinases in the Central Nervous System: Review of Genetic Studies in Mice
- (2014) Mitsue Ishisaka et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Diacylglycerol kinase establishes T cell polarity by shaping diacylglycerol accumulation at the immunological synapse
- (2014) A. Chauveau et al. Science Signaling
- CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells
- (2014) Debbie C Strachan et al. OncoImmunology
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- TLR agonists: our best frenemy in cancer immunotherapy
- (2013) Sabina Kaczanowska et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Diacylglycerol Kinase Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
- (2013) C. L. Dominguez et al. Cancer Discovery
- Abrogation of Src Homology Region 2 Domain-Containing Phosphatase 1 in Tumor-Specific T Cells Improves Efficacy of Adoptive Immunotherapy by Enhancing the Effector Function and Accumulation of Short-Lived Effector T Cells In Vivo
- (2012) I. M. Stromnes et al. JOURNAL OF IMMUNOLOGY
- Adoptive Transfer of siRNA Cblb-Silenced CD8+ T Lymphocytes Augments Tumor Vaccine Efficacy in a B16 Melanoma Model
- (2012) Reinhard Hinterleitner et al. PLoS One
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells
- (2011) Katarzyna Karwacz et al. EMBO Molecular Medicine
- SAP-Mediated Inhibition of Diacylglycerol Kinase Regulates TCR-Induced Diacylglycerol Signaling
- (2011) G. Baldanzi et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response
- (2009) Saba Alzabin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels
- (2009) Ulrike Lorenz IMMUNOLOGICAL REVIEWS
- Toll-like receptor agonists in cancer therapy
- (2009) Sylvia Adams Immunotherapy
- Pattern recognition receptors and control of adaptive immunity
- (2008) Noah W. Palm et al. IMMUNOLOGICAL REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started